Loading
A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05498428 by Janssen Research & Development, LLC, with 520 participants planned, started 2022-11-11 and due to reach its primary completion in 2027-08-17. Interventions recorded: Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC) and Low Molecular Weight Heparin (LMWH).
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Pemetrexed and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Carboplatin and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.